Click here to learn about Academy events, publications and initiatives around COVID-19.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

Support The World's Smartest Network

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.

Alzheimer's Disease Therapeutics: Alternatives to Amyloid 2020



Alzheimer's Disease Therapeutics: Alternatives to Amyloid 2020

Friday, December 4, 2020, 10:30 AM - 5:00 PM EST


Presented By

The New York Academy of Sciences


The prevalence of Alzheimer’s disease (AD) is increasing in the US and worldwide. Currently more than five million people in the US suffer from AD, and this number is projected to more than double by 2050. Despite this, there are no approved disease-modifying therapeutics for this devastating neurodegenerative disorder. Although amyloid pathology is a hallmark of AD, recent clinical trials targeting amyloid have yielded disappointing results leading to increased efforts to identify new disease drivers and alternative drug targets. Moreover, there is a great need for improved tools to detect AD in its earliest stages, when therapies are likely to be most effective. This one-day symposium will feature the latest research on topics including neuroinflammation, early detection and diagnostics, sex differences and lifestyle factors, and highlight promising avenues for therapeutic development in AD.

Call for Abstracts

You are invited to submit a poster abstract which will be displayed virtually on our website. See here for submission guidelines. For complete submission instructions, please visit our online portal. The deadline for abstract submission is Monday, October 5, 2020.


Nonmember Academia, Faculty, etc.
Nonmember Corporate, Other
Nonmember Not for Profit
Nonmember Student, Undergrad, Grad, Fellow
Member Student, Post-Doc, Fellow

Scientific Organizing Committee

Rudolph Tanzi, PhD

Harvard Medical School

Lisa Mosconi, PhD

Weill Cornell Medical College

George Zavoico, PhD

Cue Biopharma

Howard Fillit, MD

Alzheimer's Drug Discovery Foundation

Sonya Dougal, PhD

New York Academy of Sciences

Sara Donnelly, PhD

New York Academy of Sciences


Richard Isaacson, MD

Weill Cornell Medical College

Katerina Akassoglou, PhD

Gladstone Institutes

Beth Stevens, PhD

Harvard Medical School

Henrik Zetterberg, MD, PhD

University of Gothenburg

Jeffrey Kaye, PhD

Oregon Health & Sciences University

Maria Teresa Ferretti, PhD

University of Zurich